Full text

Turn on search term navigation

© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Acne and acne sequelae can have an important impact on patients’ quality of life, affecting interpersonal relationships and social functioning. Acne-induced scars (AIS) and acne-induced macular hyperpigmentation (AIH), in particular, are a major concern for patients with acne, as their management is challenging and often unsatisfactory. Retinoids are considered the mainstay of acne treatment because of their action on multiple pathogenetic factors, and there is increasing evidence that they can also improve AIS and AIH. Trifarotene, a topical retinoid with selectivity for retinoic acid receptor (RAR)-γ, has undergone an extensive clinical development programme, demonstrating its efficacy in treating facial and truncal acne and improving acne sequelae. In this article, we review the main evidence supporting the use of trifarotene in patients with acne and acne sequelae and provide place-in-therapy suggestions based on the experience of the Italian Acne Board with this drug in real-life practice. Trifarotene can be used successfully, as monotherapy or in association with other treatments, in most clinical settings of acne, but it plays an essential role in patients with existing AIS and AIH, those with a clinical or personal history of scarring and those who are predisposed to AIH. Owing to its long-term efficacy and tolerability, trifarotene is also a good option as a maintenance treatment. As with other topical retinoids, patients undergoing trifarotene therapy should be given advice on how to minimise local irritation when starting treatment.

Details

Title
A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board
Author
Annunziata, Maria Carmela 1 ; Barbareschi, Mauro 2 ; Bettoli, Vincenzo 3 ; Dall’Oglio, Federica 4 ; Micali, Giuseppe 4 ; Monfrecola, Giuseppe 1 ; Skroza, Nevena 5   VIAFID ORCID Logo  ; Tretti Clementoni, Matteo 6 ; Veraldi, Stefano 7 

 “Federico II” University of Naples, Dermatology Unit, Department of Clinical Medicine and Surgery, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X) 
 University of Milan, Department of Pathophysiology and Transplantation, IRCCS Ca’ Granda Foundation, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822) 
 G.I.S.E.D., Italian Group of Epidemiological Studies in Dermatology, Acne and Related Dermatoses Centre, Bologna, Italy (GRID:grid.4708.b) 
 University of Catania, Dermatology Clinic, Catania, Italy (GRID:grid.8158.4) (ISNI:0000 0004 1757 1969) 
 Sapienza University of Rome, Dermatology Unit “D. Innocenzi”, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy (GRID:grid.7841.a) 
 Laserplast Aesthetic Medicine Center, Milan, Italy (GRID:grid.7841.a) 
 Dermatological Centre in Milan, Milan, Italy (GRID:grid.7841.a) 
Pages
245-264
Publication year
2025
Publication date
Feb 2025
Publisher
Springer Nature B.V.
ISSN
21938210
e-ISSN
21909172
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3223887275
Copyright
© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.